Pelosi Giuseppe, Del Curto Barbara, Trubia Maurizio, Nicholson Andrew G, Manzotti Michela, Veronesi Giulia, Spaggiari Lorenzo, Maisonneuve Patrick, Pasini Felice, Terzi Alberto, Iannucci Antonio, Viale Giuseppe
Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine and Cancer Genetic Unit, IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.
Clin Cancer Res. 2007 Apr 1;13(7):1995-2004. doi: 10.1158/1078-0432.CCR-06-2483.
An overlapping area of gain at 3q26 has been reported in lung squamous cell carcinoma (SCC), but whether this also occurs in preneoplastic/preinvasive squamous cell proliferations and early-stage invasive carcinomas of the lung is still unknown.
We evaluated the prevalence and the clinicopathologic implications of 3q26 amplification and polysomy of chromosome 3 in 31 preneoplastic/preinvasive squamous cell lesions of the bronchial mucosa and in 139 early-stage invasive pulmonary SCC, both of limited growth within the bronchial wall [early hilar SCC (EHSCC)] and involving the pulmonary parenchyma [parenchyma-infiltrating SCC (PISCC)]. Moreover, mRNA expression of two candidate genes (h-TERC and SKI-like), both mapping to the minimal common amplification region, was also studied by quantitative real-time reverse transcription-PCR.
3q26 amplification and polysomy of chromosome 3 were confined to malignant samples, with 37% of invasive SCC, and 27% of severe dysplasias/in situ carcinomas showing these chromosomal abnormalities. Amplification (with minimal common amplification region at 3q26.2), polysomy 3, concurrent amplification and polysomy 3, or other changes (monosomy) were found in 25 SCC and 1 dysplasia, 24 and 2, 2 and 0, and 1 and 0, respectively. Amplification was significantly associated with EHSCC, polysomy 3 with PISCC. 3q26 amplification correlated with increased tumor diameter and a history of smoking, whereas polysomy 3 correlated with tumor diameter, pT class, and p53, p21, and fascin immunoreactivity. No relationship of either 3q26 gain or polysomy was found with patients' survival. Overexpression of h-TERC or SKI-like mRNA was found in 3q26-amplified or polysomic SCC, with higher levels of h-TERC in the former and of SKI-like in the latter.
3q26 amplification and chromosome 3 polysomy may be related to the development of invasive SCC, with differential distribution in tumor subsets, despite substantial histologic uniformity. Both h-TERC and SKI-like may be involved in tumor progression.
已有报道称在肺鳞状细胞癌(SCC)中存在3q26区域的重叠性增益,但这种情况是否也发生在肺的癌前/原位鳞状细胞增殖及早期浸润性癌中仍不清楚。
我们评估了3q26扩增和3号染色体多体性在31例支气管黏膜癌前/原位鳞状细胞病变以及139例早期浸润性肺SCC中的发生率及其临床病理意义,这些早期浸润性肺SCC包括在支气管壁内生长受限的[早期肺门SCC(EHSCC)]以及累及肺实质的[实质浸润性SCC(PISCC)]。此外,还通过定量实时逆转录PCR研究了两个候选基因(h-TERC和SKI样)的mRNA表达,这两个基因均定位于最小共同扩增区域。
3q26扩增和3号染色体多体性仅限于恶性样本,37%的浸润性SCC以及27%的重度发育异常/原位癌显示出这些染色体异常。在25例SCC和1例发育异常中分别发现了扩增(最小共同扩增区域位于3q26.2)、3号染色体多体性、同时存在扩增和3号染色体多体性或其他改变(单体性),其例数分别为25和1、24和2、2和0、1和0。扩增与EHSCC显著相关,3号染色体多体性与PISCC相关。3q26扩增与肿瘤直径增加和吸烟史相关,而3号染色体多体性与肿瘤直径、pT分级以及p53、p21和fascin免疫反应性相关。未发现3q26增益或多体性与患者生存率之间存在关联。在3q26扩增或多体性的SCC中发现了h-TERC或SKI样mRNA的过表达,前者中h-TERC水平较高,后者中SKI样水平较高。
尽管组织学上基本一致,但3q26扩增和3号染色体多体性可能与浸润性SCC的发生发展有关,在不同肿瘤亚群中的分布存在差异。h-TERC和SKI样可能均参与肿瘤进展。